Gilead Sciences

Open: 76.61 Close: 77.19 Change: 0.58

The stock market through the eyes of an AI: Gilead Sciences Company Inc Stock.

Are looking for the most relevant information about Gilead Sciences? Investor spend a lot of time searching for information to make investment decisions in Gilead Sciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, GILD, Inc, develop, Remdesivir, Is, and the most common words in the summary are: gilead, science, stock, job, inc, market, gild, . One of the sentences in the summary was: FDA approved Gileads Remdesivir For COVID-19 Treatment Patients With Severe Renal …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a +0.43% move from the previous day. FDA approved Gileads Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment, Including Those on Dialysis 7/14/2023.

Today's News

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis 7/14/2023. Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a +0.43% move from the previous day. FDA approved Gileads Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment. Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75 GileAD Sciences, Inc. Is increasing its Dividends To $1.37. Gilead Sciences - GILD - Stock Price Today - Zacks Is It Time to Buy GILD? Shares are up. Gilead Sciences has entered into public-private collaborations with the Clinton Health Access Initiative (CHAI) and the Penta ID network to expedite the development and marketing of dispersible HIV treatments for the paediatric population. The initial collaboration will focus on developing an experimental dispersible paediatric dosage. Remdesivir was originally created and developed by Gilead Sciences in 2009, to treat hepatitis C and respiratory syncytial virus (RSV) In February 2016, orphan designation (EU/3/16/1615) was granted by the European Commission to Gileade Sciences International Ltd, United Kingdom. Gilead Sciences agrees to sell to Europe up to 500,000 courses of remdesivir. Gilead sciences agrees to. sell to European up to. 500,00 courses of Remdesivirs Gilead Sciences, Inc. (GILD) stock has fallen -1.38% this week. The data presented on this page does not represent the view of GileAD Sciences and its employees or that of Zippia.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, GILD, Inc, develop, Remdesivir, Is, and the most common words in the summary are: gilead, science, stock, job, inc, market, gild, . One of the sentences in the summary was: FDA approved Gileads Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment, Including Those on Dialysis 7/14/2023.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #job #inc #market #gild.